Immunoregulation in Inflammatory Bowel Diseases - Current Understanding and Innovation

List of principal contributors List of chairpersons Preface SECTION I: ADVANCES IN THE PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE.- 1 Innate immune responses in inflammatory bowel disease.- 2 The adaptive immune responses in inflammatory bowel disease.-3 Relevance of bacteria in the pathogenesis of inflammatory bowel disease.- 4 Taking a toll on MD-2 in inflammatory bowel disease.-SECTION II: OPTIMIZATION IN THERAPY THROUGH IMPROVED DISEASE CLASSIFICATION?.- 5 Classification of inflammatory bowel disease can only be based on the clinical phenotype.- 6 Use of serology and genetics to differentiate inflammatory bowel disease phenotypes.- 7 Do biomarkers help to optimize therapy in inflammatory bowel disease?.- 8 Role of pharmacogenetics in the management of inflammatory bowel diseases.- SECTION III: CONVENTIONAL IMMUNOMODULATOR THERAPY.- 9 State-of-the-art therapy in accordance with guidelines.- 10 Increased risk of morbidity associated with immunomodulatory treatment in patients with inflammatory bowel diseases.- 11 Can immunomodulatory therapy be improved by metabolite measurement and combination therapy?.- SECTION IV: RELEVANCE OF BIOLOGICS.- 12 Top-down therapy for inflammatory bowel disease.- 13 'Step-up'' versus `'top-down'' strategies in inflammatory bowel disease - what do we know in 2006?.- 14 Importance of mucosal healing in Crohn's disease and ulcerative colitis.- 15 State-of-the-Art Lecture: Distinct antibacterial-defensin deficiencies in small intestinal and colonic Crohn's disease.- SECTION V: NEW THERAPEUTIC APPROACHES (PART I).- 16 Oligonucleotides - new therapeutic approaches.- 17 Probiotics in inflammatory bowel disease.- 18 Helminth ova therapy for inflammatory bowel disease.- 19 Retarded release phosphatidylcholine: a new therapeutic option for ulcerative colitis.- 20 Topical steroids - rectal application.- SECTION VI: NEW THERAPEUTIC APPROACHES (PART II).- 21 Apheresis.- 22 The evolving understanding and therapy of Crohn's disease: innate immunity and sargramostim (GM-CSF) 23.-Immunosuppression with tacrolimus, everolimus and sirolimus.- 24 T-cell modulating antibodies in inflammatory bowel disease.- Index